Key Takeaways
- • Tottenham Hotspur launched Hotspur Labs, a venture programme created with TPF Labs, the corporate venture arm of The Players Fund, the UK's first athlete-led venture capital firm, and launched last month according to the source article.
- • TPF Labs focuses on sponsorship-for-equity arrangements, targeting Series A and Series B startups that may become paying sponsors as they grow, with a long-term rather than quick-revenue horizon.
- • The model trades in non-cash assets such as stadium access, fan base, data, and pilot opportunities, with TPF Labs typically working with three to five companies per club's annual cohort.
- • The Players Fund runs a £10m generalist fund focused on B2B software and frontier AI, and its founders Fergus and Ruari Bell built the firm after advising teammates on investment decisions.
- • Como 1907's partnership with Swiss brain-health company Connectome, which received 750 brain scans in exchange for equity, illustrates how clubs can supply assets startups cannot easily assemble alone.
Summary
Tottenham Hotspur has launched Hotspur Labs, a venture programme developed in collaboration with TPF Labs, the corporate venture arm of The Players Fund. According to the source article, the programme launched last month and departs from conventional corporate venture capital by emphasising what a sports organisation can offer beyond cash, including stadium access, a global fan base, data, and the chance to test products in a live sporting environment.
The Players Fund, described as the UK's first athlete-led venture capital firm, was founded about four years ago by former footballer Fergus Bell and his brother Ruari Bell, a former rugby player. The firm began as an informal sounding board for teammates weighing investment opportunities. It now runs a £10m generalist fund with an interest in B2B software and frontier AI. TPF Labs, managed by Fergus and Ruari's sister Flora Bell, handles corporate venture work. Flora Bell, managing director of TPF Labs, said the Tottenham arrangement focuses on sponsorship for equity, with the club building early relationships with Series A and Series B companies in the expectation that some may become paying sponsors as they grow. She described this as a long-term bet rather than a quick route to revenue.
TPF Labs' approach begins with understanding how each organisation operates. Bell said the team meets staff across departments including IT, HR and legal, asking about day-to-day problems, which may be unrelated to on-field performance. These conversations inform the sourcing of companies, and the team also accepts direct applications from startups. Arrangements are bespoke and can include services, pilots, sponsorship or equity, and the club's contribution need not match a startup's core technology.
The model's clearest example is Como 1907, another TPF Labs partner. Swiss brain-health company Connectome, whose core business was in hospitals, needed data and received 750 brain scans of the academy, female and male teams in exchange for equity, according to Bell. TPF Labs also runs Juventus Forward for Juventus, with an initial cohort working in gait and motion analysis, football wearables, neurological tracking and media technologies. TPF Labs typically works with three to five companies per club cohort, and success may take the form of a financial return, a commercial partnership or a joint venture; one Como cohort company is set to launch a joint venture with the club. The source article frames the open question as whether these distinctive assets can produce repeatable, useful partnerships beyond one-off deals.
The Players Fund, described as the UK's first athlete-led venture capital firm, was founded about four years ago by former footballer Fergus Bell and his brother Ruari Bell, a former rugby player. The firm began as an informal sounding board for teammates weighing investment opportunities. It now runs a £10m generalist fund with an interest in B2B software and frontier AI. TPF Labs, managed by Fergus and Ruari's sister Flora Bell, handles corporate venture work. Flora Bell, managing director of TPF Labs, said the Tottenham arrangement focuses on sponsorship for equity, with the club building early relationships with Series A and Series B companies in the expectation that some may become paying sponsors as they grow. She described this as a long-term bet rather than a quick route to revenue.
TPF Labs' approach begins with understanding how each organisation operates. Bell said the team meets staff across departments including IT, HR and legal, asking about day-to-day problems, which may be unrelated to on-field performance. These conversations inform the sourcing of companies, and the team also accepts direct applications from startups. Arrangements are bespoke and can include services, pilots, sponsorship or equity, and the club's contribution need not match a startup's core technology.
The model's clearest example is Como 1907, another TPF Labs partner. Swiss brain-health company Connectome, whose core business was in hospitals, needed data and received 750 brain scans of the academy, female and male teams in exchange for equity, according to Bell. TPF Labs also runs Juventus Forward for Juventus, with an initial cohort working in gait and motion analysis, football wearables, neurological tracking and media technologies. TPF Labs typically works with three to five companies per club cohort, and success may take the form of a financial return, a commercial partnership or a joint venture; one Como cohort company is set to launch a joint venture with the club. The source article frames the open question as whether these distinctive assets can produce repeatable, useful partnerships beyond one-off deals.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.